News

Imaging studies don’t predict pancreatic resectability post-FOLFIRINOX


 

AT SSO 2014

"With this therapeutic modality and intensive surgical interventions, we hope that we are making an impact in these patients’ lives and improving their survival," she said.

The study was internally supported. Dr. Ferrone reported having no financial disclosures.

Pages

Recommended Reading

Endoscopic mucosal resection new gold standard for esophageal adenocarcinoma
MDedge Hematology and Oncology
Guidelines: No ink on tumor is adequate surgical margin for early-stage breast cancer
MDedge Hematology and Oncology
Esophagectomy treatment response nodes provide prognostic information
MDedge Hematology and Oncology
Thyroid cancer rise mostly overdiagnosis
MDedge Hematology and Oncology
VIDEO: How to improve cancer survivorship planning
MDedge Hematology and Oncology
Prior resection poses certain risks in lung transplantation
MDedge Hematology and Oncology
Positive surgical margins do not independently predict prostate cancer mortality
MDedge Hematology and Oncology
Team planning cuts pancreatectomy readmissions
MDedge Hematology and Oncology
High posthepatectomy bilirubin bodes ill for patients
MDedge Hematology and Oncology
Even when curative-intent surgery fails, patients retain hope
MDedge Hematology and Oncology